Sun Pharmaceutical Industries Ltd.

NSE: SUNPHARMA BSE: 524715 SECTOR: Pharmaceuticals & Drugs  255k   2k   421

990.70
+6.50 (0.66%)
NSE: 29 Mar 4:00 PM

Price Summary

Today's High

₹ 996.65

Today's Low

₹ 978

52 Week High

₹ 1071.9

52 Week Low

₹ 789.9

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

237702.12 Cr.

Enterprise Value

242035.87 Cr.

No. of Shares

239.93 Cr.

P/E

166.77

P/B

8.96

Face Value

₹ 1

Div. Yield

1.01 %

Book Value (TTM)

₹  110.51

CASH

534.96 Cr.

DEBT

4868.71 Cr.

Promoter Holding

54.48 %

EPS (TTM)

₹  5.94

Sales Growth

10.41%

ROE

-0.39 %

ROCE

2.19%

Profit Growth

-111.87 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Sun Pharmaceutical Industries Ltd.

Molxvir Gloeye Prazopress Pantocid Predmet Garlic Pearls REVITAL VOLINI PEPFIZ Diamox Deslor Cepodem Colvac Livcare Montek Mox CV Nexito

Index Presence

The company is present in 40 Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year10.41%
3 Year14.79%
5 Year15.19%

Profit Growth

1 Year-111.87%
3 Year-149.66%
5 Year-218.92%

ROE%

1 Year-0.39%
3 Year5.5%
5 Year4.3%

ROCE %

1 Year2.19%
3 Year5.95%
5 Year4.9%

Debt/Equity

0.198

Price to Cash Flow

31.13

Interest Cover Ratio

1.7906725070858

CFO/PAT (5 Yr. Avg.)

1.69365753902348

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2022 54.48 1.92
Sep 2022 54.48 2.53
Jun 2022 54.48 4.04
Mar 2022 54.48 5.57
Dec 2021 54.48 4.79
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 2267.76 Cr.
  • The company has an efficient Cash Conversion Cycle of -12.5980930946973 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.69365753902348.
  • The company has a high promoter holding of 54.48%.

 Limitations

  • The company has shown a poor profit growth of -149.657219446042% for the Past 3 years.
  • The company has shown a poor revenue growth of 14.7943520308848% for the Past 3 years.
  • Company has a poor ROE of 5.49631092220233% over the past 3 years.
  • The company is trading at a high EV/EBITDA of 43.4442.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022
Net Sales 3770.66 4006.88 4932.88 5285.29 4645.75
Total Expenditure 3122.29 3147.12 3610.44 3622.12 3652.97
Operating Profit 648.37 859.76 1322.44 1663.17 992.78
Other Income 313.25 440.49 176.21 41.71 74.63
Interest 85.47 91.19 87.07 92.77 130.89
Depreciation 355.24 354.14 374.5 383.95 430.44
Exceptional Items 0 -1654.96 0 0 0
Profit Before Tax 520.91 -800.04 1037.08 1228.16 506.08
Tax 5.48 486.17 25.28 15.15 19.35
Profit After Tax 515.43 -1286.21 1011.8 1213.01 486.73
Adjusted EPS (Rs) 2.15 -5.36 4.22 5.06 2.03

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Net Sales 8982.49 10303.21 12531.93 14116.05 15585.98
Total Expenditure 8127.8 8561.66 9820.28 11859.04 12917.42
Operating Profit 854.69 1741.55 2711.65 2257.01 2668.56
Other Income 1251.61 1286.15 1510.92 192.07 1196.88
Interest 388.31 540.92 408.01 267.52 388.1
Depreciation 487.24 552.95 561.56 1236.43 1349.95
Exceptional Items -950.5 -1214.38 0 -89.56 -1820.53
Profit Before Tax 280.25 719.45 3253 855.57 306.86
Tax -25.39 -97.15 41.86 13.17 406.85
Net Profit 305.64 816.6 3211.14 842.4 -99.99
Adjusted EPS (Rs.) 1.27 3.4 13.38 3.51 -0.42

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Equity and Liabilities
Share Capital 239.93 239.93 239.93 239.93 239.93
Total Reserves 22082.68 22603.68 24156.29 26698.54 24348.02
Borrowings 1564.69 1422.5 1256.69 5300.02 4865.64
Other N/C liabilities 683.99 514.09 1890.56 1928.04 1498.21
Current liabilities 12558.42 13271.83 11203.74 9951.33 10105.83
Total Liabilities 37129.71 38052.03 38747.21 44117.86 41057.63
Assets
Net Block 4644.57 4978.42 5228.74 9668.79 9712.78
Capital WIP 830.39 456.25 384.35 459.2 358.94
Intangible WIP 157.45 186.29 212.26 631.18 469.7
Investments 18310.5 17656.16 16966.65 15506.2 15355.83
Loans & Advances 3600.73 3592.57 4013.14 5120.85 5451.94
Other N/C Assets 10.86 12.57 0.95 1.56 4.69
Current Assets 9575.21 11169.77 11941.12 12730.08 9703.75
Total Assets 37129.71 38052.03 38747.21 44117.86 41057.63
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Profit from operations 280.25 719.45 3253 855.57 306.86
Adjustment -294.77 448.66 -217.09 1717.87 1266.29
Changes in Assets & Liabilities -865.29 111.5 -1393 -2752.28 3903.67
Tax Paid -291.42 -37.43 -337.06 -237.67 2159.54
Operating Cash Flow -1171.23 1242.18 1305.85 -416.51 7636.36
Investing Cash Flow 1393.61 431.37 1483.04 1452.47 -2697.04
Financing Cash Flow -272.1 -1468.59 -2871.15 -999.73 -4870.85
Net Cash Flow -49.72 204.96 -82.26 36.23 68.47

Corporate Actions

Investors Details

PARTICULARS Dec 2021% Mar 2022% Jun 2022% Sep 2022% Dec 2022%
Promoters 54.48 54.48 54.48 54.48 54.48
shanghvi finance p... 40.00 0.01 0.01 0.01 0.01
dilip shantilal sh... 9.60 9.60 9.60 9.60 9.60
viditi investment ... - 8.37 8.37 8.37 8.37
tejaskiran pharmac... - 8.12 8.12 8.12 8.12
family investment ... - 7.60 7.60 7.60 7.60
quality investment... - 7.60 7.60 7.60 7.60
virtuous finance p... - 4.04 4.04 4.04 4.04
virtuous share inv... - 3.49 3.49 3.49 3.49
aditya medisales l... 1.67 1.67 1.67 1.67 1.67
raksha s.valia 1.41 1.41 1.41 1.41 1.41
sholapur organics ... - 0.67 0.67 0.67 0.67
sudhir valia 0.60 0.60 0.60 0.60 0.60
unimed investments... 0.43 0.43 0.43 0.43 0.43
vibha dilip shangh... 0.37 0.37 0.37 0.37 0.37
vidhi dilip shangh... 0.12 0.12 0.12 0.12 0.12
aalok dilip shangh... 0.12 0.12 0.12 0.12 0.12
jeevanrekha invest... - 0.06 0.06 0.06 0.06
shanghvi family & ... 0.05 0.05 0.05 0.05 0.05
shanghvi family & ... - - - - -
shanghvi family & ... - - - - -
package investrade... - 0.04 0.04 0.04 0.04
kumud s. shanghvi 0.01 0.01 0.01 0.01 0.01
PARTICULARS Dec 2021% Mar 2022% Jun 2022% Sep 2022% Dec 2022%
Investors 45.52 45.52 45.52 45.52 45.52
life insurance cor... 5.89 5.53 6.06 6.06 5.95
life insurance cor... - - - - -
icici prudential v... 3.42 - - 3.12 2.96
icici prudential v... - - 3.00 - -
sbi-etf nifty 50 a... - - - - 1.30
reliance capital t... - - - - -
reliance capital t... 1.28 - - - -
lakshdeep investme... 1.31 1.46 1.46 1.46 1.46
government of sing... 1.38 1.25 1.31 1.25 1.36
reliance capital t... - - - - -
sbi blue chip fund... - - - 1.28 -
sbi - eft nifty 50 - - 1.16 - -
aditya birla sun l... - - - - -
matthews pacific t... 1.01 - - - -
uti and its scheme... - - - - -
iepf 0.05 - 0.02 0.02 0.05

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Sun Pharma inks pact to acquire 60% stake in Vivaldis Health and Foods25 Mar 2023, 11:02AM Sun Pharmaceutical Industries informs about loss of share certificates21 Mar 2023, 4:52PM Sun Pharmaceutical Industries informs about loss of share certificates17 Mar 2023, 5:06PM Sun Pharmaceutical Industries informs about analyst meet 14 Mar 2023, 11:30AM Sun Pharmaceutical Industries informs about loss of share certificates13 Mar 2023, 2:45PM Sun Pharmaceutical Industries informs about disclosure 8 Mar 2023, 3:23PM Sun Pharmaceutical Industries completes acquisition of Concert Pharmaceuticals 8 Mar 2023, 11:59AM Sun Pharmaceutical Industries informs about analyst meet 3 Mar 2023, 4:57PM Sun Pharmaceutical Industries informs about disclosure 1 Mar 2023, 4:22PM Sun Pharmaceutical Industries to acquire stakes in Agatsa Software, Remidio Innovative Solutions20 Feb 2023, 10:30AM Sun Pharmaceutical Industries informs about of issuance of duplicate share certificates18 Feb 2023, 12:34PM Sun Pharma’s arm recalling over 34,000 bottles of generic medication in US13 Feb 2023, 11:28AM Sun Pharmaceutical Industries informs about press release 10 Feb 2023, 12:54PM Sun Pharma’s arm receives USFDA’s approval for Generic Lenalidomide Capsules10 Feb 2023, 12:12PM Sun Pharmaceutical Industries informs about analyst meet3 Feb 2023, 5:15PM Sun Pharmaceutical Industries informs about audio recording of call1 Feb 2023, 9:34AM Sun Pharmaceutical Industries reports marginal rise in Q3 consolidated net profit31 Jan 2023, 3:20PM Sun Pharma Inds. - Quaterly Results31 Jan 2023, 1:28PM Sun Pharma Inds. - Quaterly Results31 Jan 2023, 1:28PM Sun Pharma Inds. - Quaterly Results31 Jan 2023, 1:28PM Sun Pharma acquires three anti-inflammatory brands from Aksigen Hospital Care30 Jan 2023, 2:30PM Sun Pharmaceutical Industries informs about outcome of postal ballot 28 Jan 2023, 12:38PM Sun Pharmaceutical Industries informs about loss of share certificates27 Jan 2023, 5:11PM Sun Pharmaceutical Industries launches SEZABY in U.S.25 Jan 2023, 3:17PM Sun Pharma to acquire Concert Pharmaceuticals 20 Jan 2023, 10:08AM USFDA pulls up Sun Pharma for manufacturing lapses in Halol plant14 Jan 2023, 3:41PM Sun Pharmaceutical Industries launches Palbociclib in India11 Jan 2023, 12:14PM Sun Pharmaceutical Industries informs about newspaper advertisements 26 Dec 2022, 4:44PM Sun Pharmaceutical Industries informs about sustainability report24 Dec 2022, 11:59AM Sun Pharma receives warning letter from USFDA for Halol facility17 Dec 2022, 4:13PM Sun Pharmaceutical Industries informs about updates8 Dec 2022, 5:14PM USFDA lists Sun Pharma's Halol facility under import alert8 Dec 2022, 12:07PM Sun Pharma’s US-based unit recalls 14,064 cartons of medication to treat erosive esophagitis5 Dec 2022, 11:17AM Sun Pharmaceutical Industries informs about loss of share certificates2 Dec 2022, 11:10AM Sun Pharma, SPARC get nod from USFDA for SEZABY 18 Nov 2022, 2:09PM Sun Pharmaceutical Industries informs about press release18 Nov 2022, 10:28AM Sun Pharmaceutical Industries informs about press release9 Nov 2022, 4:09PM Sun Pharma, SPARC enter into license agreement for commercialization of phenobarbital for injection in US9 Nov 2022, 1:01PM Sun Pharma's Mohali plant receives OAI status from USFDA9 Nov 2022, 9:59AM Sun Pharmaceutical Industries informs about issuance of duplicate share certificates2 Nov 2022, 10:34AM Sun Pharmaceutical Industries reports 8% rise in Q2 consolidated net profit1 Nov 2022, 3:35PM Sun Pharma Inds. - Quaterly Results1 Nov 2022, 1:36PM Sun Pharma Inds. - Quaterly Results1 Nov 2022, 1:36PM Sun Pharma Inds. - Quaterly Results1 Nov 2022, 1:36PM Sun Pharmaceutical Industries informs about loss of share certificates18 Oct 2022, 9:33AM Sun Pharmaceutical Industries informs about disclosure 21 Sep 2022, 5:22PM Sun Pharmaceutical Industries informs about closure of trading window21 Sep 2022, 4:52PM Sun Pharmaceutical Industries informs about details of loss of certificate17 Sep 2022, 12:10PM USFDA concludes inspection at Sun Pharmaceutical Industries’ Mohali facility16 Aug 2022, 2:38PM Sun Pharmaceutical Industries informs about press release3 Aug 2022, 9:44AM

Sun Pharma Inds. Stock Price Analysis and Quick Research Report. Is Sun Pharma Inds. an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Sun Pharma Inds. and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 7636.36 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Sun Pharma Inds. has a Debt to Equity ratio of 0.198 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Sun Pharma Inds. , the EPS growth was -111.868413557391 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Sun Pharma Inds. has OPM of 17.1215412826142 % which is a good sign for profitability.
     
  • ROE: Sun Pharma Inds. have a poor ROE of -0.388111574605804 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Sun Pharma Inds.

X